StockCIK 1377121

Protagonist Therapeutics, Inc (PTGX): Insider Trades and Fund Holdings

In the past 12 months, Protagonist Therapeutics, Inc insiders reported 0 open-market purchases worth $0 and 4 sales worth $26.6M; 4 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$26.6MSold by insiders, 12 months

2Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 2, 2026.

Recent PTGX insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 2	Sep 30	Asif AliCFO	CFO	▼ SELL10b5-1	58,629	141.78	$8.31M	−50%	Form 4 ↗
Sep 10	Sep 9	Patel Dinesh V Ph DCEO	CEO	▼ SELL10b5-1	63,548	146.18	$9.29M	−11%	Form 4 ↗
Sep 10	Sep 8	Patel Dinesh V Ph DCEO	CEO	▼ SELL10b5-1	54,174	145.87	$7.90M	−9.4%	Form 4 ↗
Sep 10	Sep 10	Patel Dinesh V Ph DCEO	CEO	▼ SELL10b5-1	7,278	144.10	$1.05M	−1.4%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Asif Ali	CFO	0	$0	1	$8.31M	Oct 2, 2026
Patel Dinesh V Ph D	CEO	0	$0	3	$18.2M	Sep 10, 2026

Tracked funds that report PTGX

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Bridgewater Associates	Q2 2026	9,269	$1.14M	0.00%	▲ +75.7%
Duquesne Family Office	Q2 2026	208,900	$26K	0.59%	▲ +30.8%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →